Apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
underutilized	underutilized	O	O	O	O
therapy	therapy	O	O	O	O
for	for	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
dopaminergic	dopaminergic	O	O	O	O
drug	drug	O	O	O	O
ever	ever	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
treat	treat	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

While	while	O	O	O	O
powerful	powerful	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
effects	effects	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
observed	observed	O	O	O	O
as	as	O	O	O	O
early	early	O	O	O	O
as	as	O	O	O	O
1951	1951	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
potential	potential	O	O	O	O
of	of	O	O	O	O
treating	treating	O	O	O	O
fluctuating	fluctuating	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
by	by	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
only	only	O	O	O	O
recently	recently	O	O	O	O
become	become	O	O	O	O
the	the	O	O	O	O
subject	subject	O	O	O	O
of	of	O	O	O	O
systematic	systematic	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
small	small	O	O	O	O
scale	scale	O	O	O	O
clinical	clinical	O	O	O	O
trials	trials	O	O	O	O
have	have	O	O	O	O
unequivocally	unequivocally	O	O	O	O
shown	shown	O	O	O	O
that	that	O	O	O	O
intermittent	intermittent	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
injections	injections	O	O	O	O
produce	produce	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
benefit	benefit	O	O	O	O
close	close	O	O	O	O
if	if	O	O	O	O
not	not	O	O	O	O
identical	identical	O	O	O	O
to	to	O	O	O	O
that	that	O	O	O	O
seen	seen	O	O	O	O
with	with	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
that	that	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
rescue	rescue	O	O	O	O
injections	injections	O	O	O	O
can	can	O	O	O	O
reliably	reliably	O	O	O	O
revert	revert	O	O	O	O
off-periods	off-periods	O	O	O	O
even	even	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
complex	complex	O	O	O	O
on-off	on-off	O	O	O	O
motor	motor	O	O	O	O
swings	swings	O	O	O	O
.	.	O	O	O	O

Continuous	continuous	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
infusions	infusions	O	O	O	O
can	can	O	O	O	O
reduce	reduce	O	O	O	O
daily	daily	O	O	O	O
off-time	off-time	O	O	O	O
by	by	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
group	group	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
appears	appears	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
stronger	stronger	O	O	O	O
effect	effect	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
generally	generally	O	O	O	O
seen	seen	O	O	O	O
with	with	O	O	O	O
add-on	add-on	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
oral	oral	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
agonists	agonists	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
COMT	comt	O	O	O	O
inhibitors	inhibitors	O	O	O	O
.	.	O	O	O	O

Extended	extended	O	O	O	O
follow-up	follow-up	O	O	O	O
studies	studies	O	O	O	O
of	of	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
8	8	O	O	O	O
years	years	O	O	O	O
have	have	O	O	O	O
demonstrated	demonstrated	O	O	O	O
long-term	long-term	O	O	O	O
persistence	persistence	O	O	O	O
of	of	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
efficacy	efficacy	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
convincing	convincing	O	O	O	O
clinical	clinical	O	O	O	O
evidence	evidence	O	O	O	O
that	that	O	O	O	O
monotherapy	monotherapy	O	O	O	O
with	with	O	O	O	O
continuous	continuous	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
infusions	infusions	O	O	O	O
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
marked	marked	O	O	O	O
reductions	reductions	O	O	O	O
of	of	O	O	O	O
preexisting	preexisting	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
main	main	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
are	are	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
cutaneous	cutaneous	O	O	O	O
tolerability	tolerability	O	O	O	O
problems	problems	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
sedation	sedation	O	O	O	O
and	and	O	O	O	O
psychiatric	psychiatric	O	DISEASE	OTHERS	I
complications	complications	O	O	O	O
play	play	O	O	O	O
a	a	O	O	O	O
lesser	lesser	O	O	O	O
role	role	O	O	O	O
.	.	O	O	O	O

Given	given	O	O	O	O
the	the	O	O	O	O
marked	marked	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
in	in	O	O	O	O
fluctuating	fluctuating	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
this	this	O	O	O	O
approach	approach	O	O	O	O
seems	seems	O	O	O	O
to	to	O	O	O	O
deserve	deserve	O	O	O	O
more	more	O	O	O	O
widespread	widespread	O	O	O	O
clinical	clinical	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

